|
1
|
Sanai N, Polley MY, McDermott MW, Parsa AT
and Berger MS: An extent of resection threshold for newly diagnosed
glioblastomas. J Neurosurg. 115:3–8. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Stupp R, Mason WP, van den Bent MJ, Weller
M, Fisher B, Taphoorn MJ, Belanger K, Brandes AA, Marosi C, Bogdahn
U, et al European Organisation for Research and Treatment of Cancer
Brain Tumor and Radiotherapy Groups; National Cancer Institute of
Canada Clinical Trials Group: Radiotherapy plus concomitant and
adjuvant temozolomide for glioblastoma. N Engl J Med. 352:987–996.
2005. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Westphal M, Ram Z, Riddle V, Hilt D and
Bortey E; Executive Committee of the Gliadel Study Group: Gliadel
wafer in initial surgery for malignant glioma: Long-term follow-up
of a multicenter controlled trial. Acta Neurochir (Wien).
148:269–275. 2006. View Article : Google Scholar
|
|
4
|
Claes A, Idema AJ and Wesseling P: Diffuse
glioma growth: A guerilla war. Acta Neuropathol. 114:443–458. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Minniti G, Amelio D, Amichetti M, Salvati
M, Muni R, Bozzao A, Lanzetta G, Scarpino S, Arcella A and Enrici
RM: Patterns of failure and comparison of different target volume
delineations in patients with glioblastoma treated with conformal
radiotherapy plus concomitant and adjuvant temozolomide. Radiother
Oncol. 97:377–381. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Ishizuka M, Abe F, Sano Y, Takahashi K,
Inoue K, Nakajima M, Kohda T, Komatsu N, Ogura S and Tanaka T:
Novel development of 5-aminolevurinic acid (ALA) in cancer
diagnoses and therapy. Int Immunopharmacol. 11:358–365. 2011.
View Article : Google Scholar
|
|
7
|
Yamamoto J: A role of 5-aminolevulinic
acid for treating malignant gliomas: Clinical implications and
future prospects (Review). ALA-Porphyrin Sci. 4:3–12. 2016.
|
|
8
|
Stummer W, Pichlmeier U, Meinel T,
Wiestler OD, Zanella F and Reulen HJ; ALA-Glioma Study Group:
Fluorescence-guided surgery with 5-aminolevulinic acid for
resection of malignant glioma: A randomised controlled multicentre
phase III trial. Lancet Oncol. 7:392–401. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Yamamoto J, Kitagawa T, Akiba D and
Nishizawa S: 5-Aminolevulinic acid-induced fluorescence in
cerebellar primary central nervous system lymphoma: A case report
and literature review. Turk Neurosurg. 25:796–800. 2015.PubMed/NCBI
|
|
10
|
Yamamoto J, Takahashi M, Idei M, et al: A
pitfall of fluorescence-guided surgery with 5-aminolevulinic acid
for the treatment of malignant brain tumor -case report-.
ALA-Porphyrin Sci. 1:61–66. 2012.
|
|
11
|
Luksiene Z, Berg K and Moan J: Combination
of photodynamic therapy and X-irradiation: A study on 5-ALA
radiomodifying properties. SPIE. 2325:306–311. 1994.
|
|
12
|
Berg K, Luksiene Z, Moan J and Ma L:
Combined treatment of ionizing radiation and photosensitization by
5-aminolevulinic acid-induced protoporphyrin IX. Radiat Res.
142:340–346. 1995. View
Article : Google Scholar : PubMed/NCBI
|
|
13
|
Schaffer M, Schaffer PM, Corti L, Gardiman
M, Sotti G, Hofstetter A, Jori G and Dühmke E: Photofrin as a
specific radiosensitizing agent for tumors: Studies in comparison
to other porphyrins, in an experimental in vivo model. J Photochem
Photobiol B. 66:157–164. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Yamamoto J, Ogura S, Tanaka T, Kitagawa T,
Nakano Y, Saito T, Takahashi M, Akiba D and Nishizawa S:
Radiosensitizing effect of 5-aminolevulinic acid-induced
protoporphyrin IX in glioma cells in vitro. Oncol Rep.
27:1748–1752. 2012.PubMed/NCBI
|
|
15
|
Yamamoto J, Ogura S, Shimajiri S, Nakano
Y, Akiba D, Kitagawa T, Ueta K, Tanaka T and Nishizawa S:
5-Aminolevulinic acid-induced protoporphyrin IX with multi-dose
ionizing irradiation enhances host antitumor response and strongly
inhibits tumor growth in experimental glioma in vivo. Mol Med Rep.
11:1813–1819. 2015.
|
|
16
|
Kitagawa T, Yamamoto J, Tanaka T, Nakano
Y, Akiba D, Ueta K and Nishizawa S: 5-Aminolevulinic acid strongly
enhances delayed intracellular production of reactive oxygen
species (ROS) generated by ionizing irradiation: Quantitative
analyses and visualization of intracellular ROS production in
glioma cells in vitro. Oncol Rep. 33:583–590. 2015.
|
|
17
|
Takahashi J, Misawa M, Murakami M, Mori T,
Nomura K and Iwahashi H: 5-Aminolevulinic acid enhances cancer
radiotherapy in a mouse tumor model. Springerplus. 2:6022013.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Kamada Y, Murayama Y, Harada K, Nishimura
M, Kondo Y, Konishi H, Morimura R, Komatsu S, Shiozaki A, Kuriu Y,
et al: Radiosensitizing effect of 5-aminolevulinic acid (5-ALA) in
Colon cancer. Gan To Kagaku Ryoho. 41:1608–1610. 2014.In
Japanese.
|
|
19
|
Wang D, Cvetkovic B, Gupta R, Chen L, Ma
CMC, Zhang Q and Zeng J: Radiatoin therapy combined with
5-amiolevulinic acid: A preliminary study with an in vivo mouse
model implanted with human PC-3 tumor cells. Int J Radiat Oncol
Biol Phys. 93:e5222015. View Article : Google Scholar
|
|
20
|
Takahashi J, Misawa M and Iwahashi H:
Transcriptome analysis of porphyrin-accumulated and
x-ray-irradiated cell cultures under limited proliferation and
non-lethal conditions. Microarrays (Basel). 4:25–40. 2015.
View Article : Google Scholar
|
|
21
|
Riley PA: Free radicals in biology:
Oxidative stress and the effects of ionizing radiation. Int J
Radiat Biol. 65:27–33. 1994. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Hall E and Giaccia A: Physics and
chemistry of radiation absorption. Radiology for the Radiologist
Lippipncott. Williams and Wilkins; Philadelphia, PA: pp. 5–15.
2006
|
|
23
|
Takahashi J and Misawa M: Characterization
of reactive oxygen species generated by protoporphyrin IX under
X-ray irradiation. Radiat Phys Chem. 78:889–898. 2009. View Article : Google Scholar
|
|
24
|
Yamamori T, Yasui H, Yamazumi M, Wada Y,
Nakamura Y, Nakamura H and Inanami O: Ionizing radiation induces
mitochondrial reactive oxygen species production accompanied by
upregulation of mitochondrial electron transport chain function and
mitochondrial content under control of the cell cycle checkpoint.
Free Radic Biol Med. 53:260–270. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Kam WW and Banati RB: Effects of ionizing
radiation on mitochondria. Free Radic Biol Med. 65:607–619. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Azzam EI, Jay-Gerin JP and Pain D:
Ionizing radiation-induced metabolic oxidative stress and prolonged
cell injury. Cancer Lett. 327:48–60. 2012. View Article : Google Scholar
|
|
27
|
Richardson RB and Harper ME: Mitochondrial
stress controls the radiosensitivity of the oxygen effect:
Implications for radiotherapy. Oncotarget. Feb 15–2016.Epub ahead
of print.
|
|
28
|
Saenko Y, Cieslar-Pobuda A, Skonieczna M
and Rzeszowska- Wolny J: Changes of reactive oxygen and nitrogen
species and mitochondrial functioning in human K562 and HL60 cells
exposed to ionizing radiation. Radiat Res. 180:360–366. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Sugiyama Y, Hagiya Y, Nakajima M, Ishizuka
M, Tanaka T and Ogura S: The heme precursor 5-aminolevulinic acid
disrupts the Warburg effect in tumor cells and induces
caspase-dependent apoptosis. Oncol Rep. 31:1282–1286. 2014.
|
|
30
|
Kiang JG, Garrison BR, Smith JT and
Fukumoto R: Ciprofloxacin as a potential radio-sensitizer to tumor
cells and a radio-protectant for normal cells: Differential effects
on γ-H2AX formation, p53 phosphorylation, Bcl-2 production, and
cell death. Mol Cell Biochem. 393:133–143. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Ohgari Y, Miyata Y, Chau TT, Kitajima S,
Adachi Y and Taketani S: Quinolone compounds enhance
delta-aminolevulinic acid-induced accumulation of protoporphyrin IX
and photosensitivity of tumour cells. J Biochem. 149:153–160. 2011.
View Article : Google Scholar
|
|
32
|
Kanzleiter T, Rath M, Penkov D, Puchkov D,
Schulz N, Blasi F and Schürmann A: Pknox1/Prep1 regulates
mitochondrial oxidative phosphorylation components in skeletal
muscle. Mol Cell Biol. 34:290–298. 2014. View Article : Google Scholar :
|
|
33
|
Thomas MM, Trajcevski KE, Coleman SK,
Jiang M, Di Michele J, O'Neill HM, Lally JS, Steinberg GR and Hawke
TJ: Early oxidative shifts in mouse skeletal muscle morphology with
high-fat diet consumption do not lead to functional improvements.
Physiol Rep. 2:22014. View Article : Google Scholar
|
|
34
|
Wondrak GT: Redox-directed cancer
therapeutics: Molecular mechanisms and opportunities. Antioxid
Redox Signal. 11:3013–3069. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Lomax ME, Folkes LK and O'Neill P:
Biological consequences of radiation-induced DNA damage: Relevance
to radiotherapy. Clin Oncol (R Coll Radiol). 25:578–585. 2013.
View Article : Google Scholar
|
|
36
|
Barendsen GW: The relationships between
RBE and LET for different types of lethal damage in mammalian
cells: Biophysical and molecular mechanisms. Radiat Res.
139:257–270. 1994. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Leach JK, Van Tuyle G, Lin PS,
Schmidt-Ullrich R and Mikkelsen RB: Ionizing radiation-induced,
mitochondria-dependent generation of reactive oxygen/nitrogen.
Cancer Res. 61:3894–3901. 2001.PubMed/NCBI
|
|
38
|
Clayton DA: Transcription and replication
of mitochondrial DNA. Hum Reprod. 15(Suppl 2): 11–17. 2000.
View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Anderson S, Bankier AT, Barrell BG, de
Bruijn MH, Coulson AR, Drouin J, Eperon IC, Nierlich DP, Roe BA,
Sanger F, et al: Sequence and organization of the human
mitochondrial genome. Nature. 290:457–465. 1981. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Richter C, Park JW and Ames BN: Normal
oxidative damage to mitochondrial and nuclear DNA is extensive.
Proc Natl Acad Sci USA. 85:6465–6467. 1988. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Larsen NB, Rasmussen M and Rasmussen LJ:
Nuclear and mitochondrial DNA repair: Similar pathways?
Mitochondrion. 5:89–108. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Cadenas E and Davies KJ: Mitochondrial
free radical generation, oxidative stress, and aging. Free Radic
Biol Med. 29:222–230. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Babior BM: NADPH oxidase: An update.
Blood. 93:1464–1476. 1999.PubMed/NCBI
|
|
44
|
Kloskowski T, Gurtowska N, Nowak M,
Joachimiak R, Bajek A, Olkowska J and Drewa T: The influence of
ciprofloxacin on viability of A549, HepG2, A375.S2, B16 and C6 cell
lines in vitro. Acta Pol Pharm. 68:859–865. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Teng L, Nakada M, Zhao SG, Endo Y,
Furuyama N, Nambu E, Pyko IV, Hayashi Y and Hamada JI: Silencing of
ferrochelatase enhances 5-aminolevulinic acid-based fluorescence
and photodynamic therapy efficacy. Br J Cancer. 104:798–807. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Tran TT, Mu A, Adachi Y, Adachi Y and
Taketani S: Neurotransmitter transporter family including SLC6A6
and SLC6A13 contributes to the 5-aminolevulinic acid (ALA)-induced
accumulation of protoporphyrin IX and photodamage, through uptake
of ALA by cancerous cells. Photochem Photobiol. 90:1136–1143.
2014.PubMed/NCBI
|
|
47
|
Chua C, Zaiden N, Chong KH, See SJ, Wong
MC, Ang BT and Tang C: Characterization of a side population of
astrocytoma cells in response to temozolomide. J Neurosurg.
109:856–866. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Matsumoto K, Hagiya Y, Endo Y, Nakajima M,
Ishizuka M, Tanaka T and Ogura S: Effects of plasma membrane ABCB6
on 5-aminolevulinic acid (ALA)-induced porphyrin accumulation in
vitro: Tumor cell response to hypoxia. Photodiagn Photodyn Ther.
12:45–51. 2015. View Article : Google Scholar
|
|
49
|
Hayashi M, Fukuhara H, Inoue K, Shuin T,
Hagiya Y, Nakajima M, Tanaka T and Ogura S: The effect of iron ion
on the specificity of photodynamic therapy with 5-aminolevulinic
acid. PLoS One. 10:e01223512015. View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Sawamoto M, Imai T, Umeda M, Fukuda K,
Kataoka T and Taketani S: The p53-dependent expression of frataxin
controls 5-aminolevulinic acid-induced accumulation of
protoporphyrin IX and photo-damage in cancerous cells. Photochem
Photobiol. 89:163–172. 2013. View Article : Google Scholar
|
|
51
|
Kim JE, Cho HR, Xu WJ, Kim JY, Kim SK, Kim
SK, Park SH, Kim H, Lee SH, Choi SH, et al: Mechanism for enhanced
5-aminolevulinic acid fluorescence in isocitrate dehydrogenase 1
mutant malignant gliomas. Oncotarget. 6:20266–20277. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
52
|
Uhm JH, Ballman KV, Wu W, Giannini C,
Krauss JC, Buckner JC, James CD, Scheithauer BW, Behrens RJ, Flynn
PJ, et al: Phase II evaluation of gefitinib in patients with newly
diagnosed Grade 4 astrocytoma: Mayo/North Central Cancer Treatment
Group Study N0074. Int J Radiat Oncol Biol Phys. 80:347–353. 2011.
View Article : Google Scholar
|
|
53
|
Curry WT and Lim M: Immunomodulation:
checkpoint blockade etc. Neuro Oncol. 17(Suppl 7): vii26–vii31.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
54
|
Norden AD, Drappatz J and Wen PY: Novel
anti-angiogenic therapies for malignant gliomas. Lancet Neurol.
7:1152–1160. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
55
|
Cloughesy T, Finocchiaro G, Belda-Iniesta
C, Recht L, Brandes AA, Pineda E, Mikkelsen T, Chinot OL, Balana C,
Macdonald DR, et al: Randomized, double-blind, placebo-controlled,
multicenter phase II study of onartuzumab plus bevacizumab versus
placebo plus bevacizumab in patients with recurrent glioblastoma:
efficacy, safety, and hepatocyte growth factor and
O6-methylguanine-DNA methyltransferase biomarker analyses. J Clin
Oncol. Dec 5–2016.Epub ahead of print.
|
|
56
|
Pan JG and Mak TW: Metabolic targeting as
an anticancer strategy: Dawn of a new era? Sci STKE.
2007:pe142007.PubMed/NCBI
|
|
57
|
Fulda S, Galluzzi L and Kroemer G:
Targeting mitochondria for cancer therapy. Nat Rev Drug Discov.
9:447–464. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
58
|
Weinberg SE and Chandel NS: Targeting
mitochondria metabolism for cancer therapy. Nat Chem Biol. 11:9–15.
2015. View Article : Google Scholar :
|
|
59
|
Kostron H, Swartz MR, Miller DC and
Martuza RL: The interaction of hematoporphyrin derivative, light,
and ionizing radiation in a rat glioma model. Cancer. 57:964–970.
1986. View Article : Google Scholar : PubMed/NCBI
|
|
60
|
Kulka U, Schaffer M, Siefert A, Schaffer
PM, Olsner A, Kasseb K, Hofstetter A, Dühmke E and Jori G:
Photofrin as a radiosensitizer in an in vitro cell survival assay.
Biochem Biophys Res Commun. 311:98–103. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
61
|
Schaffer M, Ertl-Wagner B, Schaffer PM,
Kulka U, Jori G, Wilkowski R, Hofstetter A and Dühmke E:
Feasibility of photofrin II as a radiosensitizing agent in solid
tumors - preliminary results. Onkologie. 29:514–519.
2006.PubMed/NCBI
|
|
62
|
Chen HP, Tung FI, Chen MH and Liu TY: A
magnetic vehicle realized tumor cell-targeted radiotherapy using
low-dose radiation. J Control Release. 226:182–192. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
63
|
Yamamoto J, Yamamoto S, Hirano T, Li S,
Koide M, Kohno E, Okada M, Inenaga C, Tokuyama T, Yokota N, et al:
Monitoring of singlet oxygen is useful for predicting the
photodynamic effects in the treatment for experimental glioma. Clin
Cancer Res. 12:7132–7139. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
64
|
Yamamoto J, Kakeda S, Yoneda T, et al:
Improving contrast enhancement in magnetic resonance imaging using
5-aminolevulinic acid-induced protoporphyrin IX for high-grade
gliomas: A prospective case study and clinical implications. Oncol
Lett. In press.
|
|
65
|
Gao Z, Zheng J, Yang B, Wang Z, Fan H, Lv
Y, Li H, Jia L and Cao W: Sonodynamic therapy inhibits angiogenesis
and tumor growth in a xenograft mouse model. Cancer Lett.
335:93–99. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
66
|
Takahashi K, Hasegawa T, Ishii T, Suzuki
A, Nakajima M, Uno K, Yasuda I, Kishi A, Sadamoto K, Abe F, et al:
Antitumor effect of combination of hyperthermotherapy and
5-aminolevulinic acid (ALA). Anticancer Res. 33:2861–2866.
2013.PubMed/NCBI
|
|
67
|
Rycaj K and Tang DG: Cancer stem cells and
radioresistance. Int J Radiat Biol. 90:615–621. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
68
|
Krause M, Dubrovska A, Linge A and Baumann
M: Cancer stem cells: Radioresistance, prediction of radiotherapy
outcome and specific targets for combined treatments. Adv Drug
Deliv Rev. Feb 12–2016.Epub ahead of print. PubMed/NCBI
|
|
69
|
Tannock IF: Cancer: Resistance through
repopulation. Nature. 517:152–153. 2015. View Article : Google Scholar
|
|
70
|
Diehn M, Cho RW, Lobo NA, Kalisky T, Dorie
MJ, Kulp AN, Qian D, Lam JS, Ailles LE, Wong M, et al: Association
of reactive oxygen species levels and radioresistance in cancer
stem cells. Nature. 458:780–783. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
71
|
Yu CH and Yu CC: Photodynamic therapy with
5-aminolevulinic acid (ALA) impairs tumor initiating and
chemo-resistance property in head and neck cancer-derived cancer
stem cells. PLoS One. 9:e871292014. View Article : Google Scholar : PubMed/NCBI
|
